Exact Sciences Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer - Seite 3

References:

1. Iyer, P. G., Taylor, W. R., et al. Highly Discriminant Methylated DNA Markers for the Non-endoscopic Detection of Barrett's Esophagus. Am J Gastroenterol 2018, 113 (8), 1156-1166.
2. Iyer, P. G.,Taylor, W. R., et al. Accurate Nonendoscopic Detection of Barrett’s Esophagus by Methylated DNA Markers: A Multisite Case Control Study. Am J Gastroenterol 2020, 115 (8), 1201-1209.
3. Cook D, et al. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1): 1–26. Accessed 26 March 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887893/
4. He H, et al. Thorac Cancer. 2020 May; 11(5): 1121–1128. Accessed 26 March 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180574/
5. Then T E, et al. World J Oncol. 2020 Apr; 11(2): 55–64. Accessed 26 March 2024.
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141161/#:~:text=Backgrou ...
6. Chandar, A.K., Low, E.E., et al. Estimated Burden of Screening for Barrett’s Esophagus in the United States. Gastroenterology. Volume 165, Issue 1, p283-285.E2, July 2023.
7. National Cancer Institute. Cancer Stat Facts: Esophageal Cancer. Accessed 26 March 2024.
   https://seer.cancer.gov/statfacts/html/esoph.html
8. Eluri S, et al Am J Gastroenterol. 2022 Nov 1; 117(11): 1764–1771.
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633338/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328804544/en/

The Exact Sciences Stock at the time of publication of the news with a raise of 0,00 % to 61,69EUR on Tradegate stock exchange (28. März 2024, 10:51 Uhr).